COVID-19: Ivermectin, effective against new corona: Utah U.S. report
COVID-19: Ivermectin
Utah University:
Utah University administers the antiparasitic drug ivermectin to patients with the novel coronavirus.
“The mortality rate was reduced to about one-sixth of that of patients who were not receiving it,” a research team from the University of Utah and others summarized.
It was also effective for severely ill patients.
More accurate tests are needed for therapeutic use.
Ivermectin:
It was developed by Kitasato University / Professor Emeritus Satoshi Omura, who won the 2015 Nobel Prize in Physiology or Medicine.
It is effective in eradicating infectious diseases caused by parasites in Africa and elsewhere.
University of Utah: Research Team
Investigate about 1400 new coronavirus patients who received treatment from January to March 2020.
The mortality rate of “about 700 patients treated with ivermectin at 169 medical institutions in North America, Europe and Asia”
The mortality rate of “about 700 patients who were not treated and were treated with other drugs”
as a result:
Mortality in patients not receiving ivermectin was approximately 8%.
On the other hand, the number of patients receiving ivermectin was as low as about 1%.
Critically ill: mortality
Looking at the mortality rate of critically ill people who need ventilator,
The mortality rate of patients who do not receive is about 21%,
The mortality rate of the treated patients is about 7%.
Future: Randomized randomized controlled trial
The research team will proceed with a highly reliable trial, which will be called a randomized (randomized) controlled trial, to confirm the therapeutic effect.
Kitasato University / Satoshi Omura Memorial Research Institute / Director of Hanaki:
“I’m surprised that the mortality rate has dropped significantly at doses that were about the same as the usual doses of ivermectin so far,” he said.
Nihon Keizai Shimbun
https://r.nikkei.com/article/DGXMZO58525110X20C20A4I00000?s=4
Antiparasitic drug “ivermectin” effective against new corona: Reported in the US
Bacterial ivermectin was discovered by Satoshi Omura, who won the 2015 Nobel Prize in Physiology or Medicine.
It has been used for “onchocerciasis, which causes blindness due to parasites, and lymphatic filariasis, which causes the skin to become stiff.”
Australian team:
Reported to confirm the effect of reducing the new coronavirus in cell experiments.
It was said that the single administration could suppress the virus growth within 1-2 days.
Mainichi newspaper
Usefulness of Ivermectin in COVID-19 Illness by Amit Patel: Amit Patel
Date Written: April 19, 2020
Abstract
Importance: There is no established anti-viral therapy for treating COVID-19 illness.
Objective: To study the usefulness of Ivermectin, an antimicrobial therapy, in COVID-19 outcomes.
Design: An international, multicenter, observational propensity-score matched case-controlled study using prospectively collected data on patients diagnosed with COVID-19 between January 1, 2020 and March 31, 2020.
Setting: An international multi- institutional deidentified healthcare outcomes database.
Participants: Hospitalized patients diagnosed with COVID-19 determined by presence of a positive laboratory finding confirming SARS-CoV-2 infection.
Exposure: Ivermectin (150mcg / Kg) administered once compared with COVID-19 patients receiving medical therapy without ivermectin.
Main Outcome: The principal outcome was to assess the association of ivermectin administration with survival in COVID-19.
Results: The cohort (including 704 ivermectin treated and 704 controls) was derived from 169 hospitals across 3 continents with COVID-19 illness.The patients were matched for age, sex, race or ethnicity, comorbidities and a illness severity score (qSOFA). Of those requiring mechanical ventilation fewer patients died in the ivermectin group (7.3% versus 21.3%) and overall death rates were lower with ivermectin (1.4% versus 8.5%; HR 0.20 CI 95% 0.11-0.37, p <0.0001).
Conclusions and Relevance: The administration of ivermectin during COVID-19 illness in hospitalized patients is associated with a lower mortality and hospital length of stay.These findings require confirmation in randomized controlled trials.
Note: Conflict of Interest: Dr. Mehra reports no direct conflicts pertinent to the development of this paper.Other general conflicts include consulting relationships with Abbott, Medtronic, Janssen, Mesoblast, Portola, Bayer, NupulseCV, FineHeart, Leviticus and Triple Gene. Dr. Desai is the founder of Surgisphere Corporation, Chicago, IL.The other authors have no pertinent conflicts to report.
Ethical Approval: The data analyzes are deemed exempt from ethics review.
Keywords: covid19, ivermectin,
outcomesSSRN